MAIA Biotechnology, Inc. (MAIA)
| Market Cap | n/a |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.50M |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About MAIA
MAIA Biotechnology is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO, our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed as a second- or later line of treatment for Non-Small Cell Lung Cancer (NSCLC) for patients that have progressed beyond the standar...
Financial Performance
Financial StatementsNews
Cancer biotech MAIA Biotechnology files for a $15 million IPO
MAIA Biotechnology, a Phase 2 biotech developing targeted immunotherapies for cancer, filed on Monday with the SEC to raise up to $15 million in an initial public offering.
MAIA Biotechnology IPO Registration Document (S-1)
MAIA Biotechnology has filed to go public with an IPO on the NASDAQ.